

Felicita Andreotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3092758/publications.pdf>

Version: 2024-02-01

214
papers

40,982
citations

20036

63
h-index

2750

198
g-index

229
all docs

229
docs citations

229
times ranked

34669
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 519-528.	1.4	13
2	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
3	Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 2022, 9, 199-209.	0.7	11
4	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123.	1.3	5
5	Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS. <i>European Heart Journal</i> , 2022, 43, 2798-2800.	1.0	5
6	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 86-93.	1.4	34
7	From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19. <i>International Journal of Cardiology</i> , 2021, 326, 243-247.	0.8	14
8	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
9	Methodological education in response to the quality of COVID-19 publications. <i>Pharmacological Research</i> , 2021, 164, 105381.	3.1	2
10	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 285-289.	0.5	16
11	Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial). <i>Diagnostics</i> , 2021, 11, 229.	1.3	2
12	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684.	1.6	10
13	Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13551.	1.7	8
14	Sex- and gender-specific precision medicine for chronic coronary syndromes: challenges and opportunities. <i>Kardiologia Polska</i> , 2021, 79, 373-375.	0.3	2
15	Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1755.	1.0	1
16	Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. <i>European Cardiology Review</i> , 2021, 16, e23.	0.7	14
17	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
18	Family history in first degree relatives of patients with premature cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 333, 215-218.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1196-1206.	1.1	24
20	When a meta-analysis equals a single large-scale trial with meaningful follow-up. European Heart Journal, 2021, 42, 3884-3885.	1.0	3
21	Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?. European Heart Journal, 2021, 42, 3187-3189.	1.0	3
22	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. International Journal of Cardiology, 2021, 336, 14-21.	0.8	9
23	Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice: The Case of Heart Failure. Circulation: Heart Failure, 2021, 14, e008840.	1.6	3
24	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology, 2021, 337, 1-8.	0.8	6
25	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	2.5	0
26	Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. European Journal of Internal Medicine, 2021, 91, 26-28.	1.0	0
27	Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. JAMA Internal Medicine, 2021, 181, 1257.	2.6	1
28	Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes. European Heart Journal, 2021, 42, 4699-4700.	1.0	4
29	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110263.	1.1	5
30	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine, 2021, 22, 175-179.	0.6	3
31	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. European Heart Journal Supplements, 2021, 23, E13-E18.	0.0	10
32	Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e16-e17.	1.4	2
33	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 128-129.	1.4	19
34	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 43-56.	1.4	26
35	Aspirin in primary prevention of cardiovascular disease in the elderly. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 326-327.	1.4	2
36	Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. American Heart Journal, 2020, 220, 12-19.	1.2	37

#	ARTICLE	IF	CITATIONS
37	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. International Journal of Cardiology, 2020, 318, 160-164.	0.8	5
38	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. Journal of Cardiovascular Medicine, 2020, 21, 841-844.	0.6	5
39	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. IJC Heart and Vasculature, 2020, 28, 100524.	0.6	13
40	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace, 2020, 22, 538-546.	0.7	36
41	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. Diabetes Care, 2020, 43, 843-851.	4.3	34
42	Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation-ACS/PCI Trials. Journal of the American College of Cardiology, 2020, 75, 1727-1728.	1.2	8
43	Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity. European Heart Journal, 2020, , .	1.0	1
44	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
45	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
46	Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?. European Heart Journal, 2019, 40, 3602-3604.	1.0	3
47	In reply-Real World-TAVR: Data in Constant Flux. Mayo Clinic Proceedings, 2019, 94, 1643-1644.	1.4	0
48	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	1.4	5
49	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. Mayo Clinic Proceedings, 2019, 94, 1457-1466.	1.4	19
50	Diagnoses and outcomes in patients with suspected angina: what are they trying to tell us?. European Heart Journal, 2019, 40, 1436-1439.	1.0	1
51	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. International Journal of Cardiology, 2019, 275, 39-45.	0.8	12
52	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 55-56.	1.4	6
53	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	6.1	73
54	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 47-54.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
56	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339
57	Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 1086-1088.	1.0	4
58	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 258, 59-67.	0.8	14
59	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
60	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
61	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2018, 168, 234.	2.0	2
62	Meta-analysis of LDL-C Lowering and Mortality—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1493.	3.8	0
63	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	1.0	53
64	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
65	Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	123
66	Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 414-417.	1.2	7
67	Aspirin and the prevention of a common disease: Colorectal cancer. <i>International Journal of Cardiology</i> , 2017, 248, 394-395.	0.8	9
68	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. <i>International Journal of Cardiology</i> , 2017, 249, 249-256.	0.8	12
69	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. <i>Data in Brief</i> , 2017, 15, 532-539.	0.5	1
70	Last Word on Viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide. <i>Journal of Applied Physiology</i> , 2017, 122, 420-421.	1.2	0
71	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy. <i>Annals of Internal Medicine</i> , 2017, 167, 103.	2.0	43
72	Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures—a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0168726.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	1.8	24
74	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016, 18, 48.	1.3	4
75	Stakeholders in NOACs prescription: authors' reply. <i>Europace</i> , 2016, 18, 788.2-789.	0.7	2
76	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
77	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
78	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	1.8	11
79	Sex differences in mechanisms, presentation and management of ischaemic heart disease. <i>Atherosclerosis</i> , 2015, 241, 157-168.	0.4	113
80	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
81	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015, 17, 1007-1017.	0.7	46
82	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2015, 350, h1618-h1618.	3.0	279
83	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 201-213.	1.1	69
84	Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. <i>Thrombosis and Haemostasis</i> , 2014, 111, 385-391.	1.8	90
85	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	1.8	142
86	Meta-Analysis of Time-Related Benefits of Statin Therapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1753-1764.	0.7	80
87	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A –state-of-the-art– paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
88	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	1.2	150
89	Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2013, 158, 261.	2.0	151
90	Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. <i>Clinical Research in Cardiology</i> , 2013, 102, 279-287.	1.5	29

#	ARTICLE	IF	CITATIONS
91	Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic Vascular Disease. <i>Circulation</i> , 2013, 128, 684-686.	1.6	6
92	Leading Avoidable Cause of Premature Deaths Worldwide: Case for Obesity. <i>American Journal of Medicine</i> , 2013, 126, 97-98.	0.6	46
93	Defining the Role of Left Atrial Appendage Closure in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 79-82.	0.4	2
94	Definición del papel de la oclusión de la orejuela auricular izquierda en la fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 79-82.	0.6	6
95	Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2013, 111, 1123-1130.	0.7	239
96	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
97	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
98	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	3.0	194
99	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	1.8	154
100	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
101	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
102	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	1.8	65
103	Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: A meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2012, 222, 1-7.	0.4	36
104	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	1.0	3,465
105	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	0.6	1,313
106	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
107	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	1.0	993
108	Diurnal variation in platelet inhibition by clopidogrel. <i>Platelets</i> , 2011, 22, 579-587.	1.1	52

#	ARTICLE	IF	CITATIONS
109	Polycythemia, vascular function, and hemoglobin-nitric oxide reactions. <i>Journal of Applied Physiology</i> , 2011, 111, 331-331.	1.2	2
110	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
111	Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1210-1219.	1.7	13
112	Hemoglobin Levels, Nitric Oxide Bioavailability and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2011, 107, 1099.	0.7	1
113	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
114	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
115	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
116	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011, 7, 985-994.	1.4	87
117	Testosterone, tissue factor inhibition and vascular aging. <i>Thrombosis and Haemostasis</i> , 2010, 103, 9-10.	1.8	3
118	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	1.0	1,392
119	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318.	1.0	216
120	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
121	New Anticoagulants and the Future of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1223-1229.	0.4	5
122	Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 145, 230-232.	0.8	7
123	Genetics and Genomics in the Management of Hemostasis and Thrombosis. , 2010, , 374-389.		0
124	The unstable plaque: a broken balance. <i>European Heart Journal</i> , 2009, 30, 1821-1823.	1.0	6
125	Asymmetric dimethylarginine and impaired cardiovascular healing. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 168-171.	1.0	4
126	Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 166-172.	1.0	5

#	ARTICLE	IF	CITATIONS
127	Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPÄMINONDAS). Journal of Thrombosis and Thrombolysis, 2009, 28, 489-495.	1.0	25
128	Role of PAPP-A in atherothrombosis: Messages to take home. Atherosclerosis, 2009, 203, 353-354.	0.4	9
129	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812.	1.0	735
130	Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the â€œOPTIMIZE-ITâ€™ pilot randomized study. Journal of Cardiovascular Medicine, 2009, 10, 245-251.	0.6	18
131	Predictors of exercise-induced platelet reactivity in patients with chronic stable angina. Journal of Cardiovascular Medicine, 2009, 10, 891-897.	0.6	7
132	Hemostasis and Thrombosis. , 2009, , 755-772.		0
133	Erythropoietin in heart and vessels: focus on transcription and signalling pathways. Journal of Thrombosis and Thrombolysis, 2008, 26, 183-187.	1.0	72
134	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
135	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal, 2008, 29, 2909-2945.	1.0	2,128
136	Women and coronary disease. Heart, 2008, 94, 108-116.	1.2	55
137	Hypercoagulable States in Cardiovascular Disease. Circulation, 2008, 118, 2286-2297.	1.6	110
138	Body fat and cardiovascular risk: understanding the obesity paradox. European Heart Journal, 2008, 30, 752-754.	1.0	32
139	Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus. Journal of Cardiovascular Medicine, 2008, 9, 714-715.	0.6	0
140	Expanding the role of coagulation in arterial thrombosis: Evidence from animal models using a new factor Xa inhibitor. Thrombosis and Haemostasis, 2008, 99, 651-652.	1.8	1
141	Letter by Andreotti et al Regarding Article, â€œHemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Studyâ€™; Circulation, 2007, 115, e313; author reply e314.	1.6	2
142	IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. Heart, 2007, 93, 1412-1413.	1.2	1
143	Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine. Journal of Cardiovascular Medicine, 2007, 8, 1043.	0.6	1
144	Adjusted Indirect Meta-Analysis of Aspirin Plus Warfarin at International Normalized Ratios 2 to 3 Versus Aspirin Plus Clopidogrel After Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1637-1642.	0.7	45

#	ARTICLE	IF	CITATIONS
145	Reduced CD34+, renal anemia, and adverse outcomes. <i>American Heart Journal</i> , 2006, 152, e21.	1.2	5
146	Proteomics, metabolomics and progenitor cells in acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 85-88.	1.0	7
147	Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25â€¦307 patients. <i>European Heart Journal</i> , 2006, 27, 519-526.	1.0	263
148	Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 2075-2076.	1.0	35
149	Interplay of platelet polymorphisms, risk factors, and Von Willebrand factor, and flow-mediated conditions in determining collagenâ€™adenosine diphosphate PFA-100 results in patients with coronary artery disease. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 97-104.	0.5	6
150	Atherothrombotic Disorders. <i>Circulation</i> , 2005, 111, 1855-1863.	1.6	48
151	Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. <i>European Heart Journal</i> , 2005, 26, 2000-2006.	1.0	120
152	Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease. <i>Heart</i> , 2005, 93, 255-257.	1.2	7
153	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. <i>European Heart Journal</i> , 2005, 26, 1196-1204.	1.0	235
154	Substandard life-saving drugs: a global concern. <i>European Heart Journal</i> , 2005, 26, 858-860.	1.0	0
155	Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. <i>European Heart Journal</i> , 2005, 26, 1618-1624.	1.0	40
156	Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. <i>Cytokine</i> , 2005, 29, 187-196.	1.4	17
157	Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease. <i>American Heart Journal</i> , 2005, 149, 832-839.	1.2	65
158	Pregnancy-Associated Plasma Protein-A and Acute Coronary Syndromes: Cause or Consequence?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1583-1584.	1.2	13
159	Heart-Kidney Interactions in Ischemic Syndromes. <i>Circulation</i> , 2004, 109, e31-2; author reply e31-2.	1.6	48
160	Pregnancy-Associated Plasma Protein A as Predictor of Outcome in Patients With Suspected Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, e211-2; author reply e211-2.	1.6	25
161	Insulin-Like Growth Factor-1 as a Vascular Protective Factor. <i>Circulation</i> , 2004, 110, 2260-2265.	1.6	231
162	Favorable cardiac risk among elderly breast carcinoma survivors. <i>Cancer</i> , 2004, 100, 878-879.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 120-128.	1.1	13
164	4G/5G PAI-1 Promoter Polymorphism and Acute-Phase Levels of PAI-1 Following Coronary Bypass Surgery: A Prospective Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 149-154.	1.0	22
165	Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1107-1112.	0.4	66
166	Relation Between Platelet Response to Exercise and Coronary Angiographic Findings in Patients With Effort Angina. <i>Circulation</i> , 2003, 107, 1378-1382.	1.6	54
167	The -174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation. Is Atrial Fibrillation an Inflammatory Complication?. <i>Circulation</i> , 2003, 108, 195II-199.	1.6	264
168	IGF-1 and Macrovascular Complications of Diabetes: Alternative interpretations of recently published data. <i>Diabetes Care</i> , 2003, 26, 1653-1654.	4.3	17
169	Increased Platelet Reactivity Due to Platelet Receptor Polymorphisms? Not in the Real World. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1703-1704.	1.1	0
170	The strengths and frailties of women with cardiovascular disease. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 361-2.	0.1	0
171	Sex, survival bias, and mortality following acute myocardial infarction. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 508-10.	0.1	3
172	Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. <i>British Heart Journal</i> , 2002, 87, 107-112.	2.2	133
173	Preoperative C-reactive protein level and outcome following coronary surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2002, 22, 521-526.	0.6	44
174	Potential of Fibrinolytic Therapy in Acute Myocardial Infarction: Expanding the Role of ACE-Inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-178.	1.8	8
175	Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 123, 1092-1100.	0.4	28
176	Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. <i>American Journal of Cardiology</i> , 2002, 89, 973-975.	0.7	49
177	Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 131-138.	1.0	8
178	Potential of fibrinolytic therapy in acute myocardial infarction: expanding the role of ACE-inhibitors. <i>Thrombosis and Haemostasis</i> , 2002, 88, 176-8.	1.8	3
179	Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 26-32.	1.2	94
180	Coronary Artero-Venous Gradient of Endogenous Urokinase. <i>Thrombosis Research</i> , 2001, 103, S29-S34.	0.8	0

#	ARTICLE	IF	CITATIONS
181	The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154.	1.2	24
182	Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. <i>American Journal of Cardiology</i> , 2001, 87, 16-20.	0.7	46
183	Relation of the ~ 174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. <i>American Journal of Cardiology</i> , 2001, 88, 1125-1128.	0.7	161
184	Key references: Basic fibrinolysis and thrombolysis selected references: 1987-1997. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 61-68.	1.0	0
185	Homocysteine and risk of cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 13-21.	1.0	35
186	Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 265-269.	1.0	12
187	G20210A Prothrombin Gene Polymorphism and Extent of Coronary Disease. <i>Thrombosis and Haemostasis</i> , 2000, 84, 142-143.	1.8	6
188	The G20210A Prothrombin Mutation and the Physicians' Health Study. <i>Circulation</i> , 2000, 101, E207-8.	1.6	7
189	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000, 356, 1849-1850.	6.3	5
190	Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin. <i>Circulation</i> , 1999, 100, 793-798.	1.6	541
191	Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 207-212.	1.0	9
192	Comparison of insulin response to intravenous glucose in healed myocardial infarction, in cooled-off unstable and stable angina pectoris, and in healthy subjects. <i>American Journal of Cardiology</i> , 1999, 84, 870-875.	0.7	1
193	Preinfarction Angina and Improved Reperfusion of the Infarct-related Artery. <i>Thrombosis and Haemostasis</i> , 1999, 82, 68-72.	1.8	8
194	Platelet and Thrombin Activity Following Cardiac Catheterization Despite Treatment with Aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 141-145.	1.0	3
195	Ischaemic preconditioning. <i>Lancet, The</i> , 1996, 348, 204.	6.3	13
196	Different effects of lipopolysaccharide on plasminogen activator inhibitor-1 production in aortic media in vivo and in culture. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 215-223.	1.0	1
197	Preinfarction Angina as a Predictor of More Rapid Coronary Thrombolysis in Patients with Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1996, 334, 7-12.	13.9	228
198	Temporal Relation Between Ischemic Episodes and Activation of the Coagulation System in Unstable Angina. <i>Circulation</i> , 1996, 93, 2121-2127.	1.6	38

#	ARTICLE	IF	CITATIONS
199	Serum Lipoprotein(a) Level Is Related to Thrombin Generation and Spontaneous Intermittent Coronary Occlusion in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1996, 94, 2072-2076.	1.6	27
200	Circadian fluctuation of fibrinolytic factors in blood. <i>Developments in Cardiovascular Medicine</i> , 1996, , 185-199.	0.1	0
201	Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. <i>Journal of the American College of Cardiology</i> , 1995, 26, 662-667.	1.2	42
202	Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. <i>American Heart Journal</i> , 1994, 127, 607-612.	1.2	157
203	Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. <i>Lancet, The</i> , 1993, 342, 937-938.	6.3	15
204	Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1377-1381.	1.2	29
205	High-dose aspirin, thrombin, and coronary angioplasty. <i>Lancet, The</i> , 1993, 341, 1161-1162.	6.3	3
206	Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations. <i>Fibrinolysis</i> , 1992, 6, 3-4.	0.5	152
207	Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 1393-1398.	0.7	8
208	Circadian Variation of Fibrinolytic Activity in Blood. <i>Chronobiology International</i> , 1991, 8, 336-351.	0.9	146
209	Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. <i>American Journal of Cardiology</i> , 1991, 68, 1295-1299.	0.7	26
210	Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 65, 1051-1056.	0.7	27
211	Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1990, 16, 1553-1560.	1.2	53
212	Earlier Recanalisation Follows Bolus Administration of Tissue-Plasminogen Activator in Patients with Acute Myocardial Infarction. <i>Clinical Science</i> , 1989, 76, 37P-37P.	0.0	0
213	Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. <i>American Journal of Cardiology</i> , 1988, 62, 635-637.	0.7	432
214	Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?. <i>Vessel Plus</i> , 0, 2021, .	0.4	2